Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Esplugues De Llobregat – page 312

3 740 clinical trials in Esplugues De Llobregat, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Esplugues De Llobregat at a glance
3 740
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 740 trials in Esplugues De Llobregat

Open in trial search

Study on Ibrutinib and Drug Combination for Patients with Generalized Mantle Cell Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Ibrutinib
  • Sponsor:Klinikum Der Universitat Munchen AöR

Primary amyloidosis

Not recruiting

Study on Birtamimab and Bortezomib for Patients with Advanced Light Chain Amyloidosis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Birtamimab
  • Sponsor:Prothena Biosciences Limited

Study on Evolocumab for Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Evolocumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Study on EYE103 and Ranibizumab for Patients with Diabetic Macular Edema

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:EYE103
  • Sponsor:Eyebiotech Limited

Study on Durvalumab for Patients with Completely Removed Non-Small Cell Lung Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Clinipace Global Limited

Narcolepsy

Not recruiting

Study on the Safety and Effectiveness of ALKS 2680 for Patients with Narcolepsy Type 1

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ALKS 2680
  • Sponsor:Alkermes Inc.

Study of Tiragolumab and Atezolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study on the Effectiveness and Safety of Remibrutinib for Teens with Chronic Spontaneous Urticaria Not Controlled by H1-Antihistamines

Registered drug
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Other cities in Spain

The busiest research cities in the country

All 210 cities in Spain

Clinical research in Esplugues De Llobregat

What the registry says about research in the country

01 Pediatric Oncology Research

Innovative clinical trials focusing on pediatric cancers include studies for neuroblastoma, hepatic tumors, and various sarcomas. Research efforts target both primary and refractory disease states.

  • High-risk neuroblastoma treatments
  • Hepatoblastoma and hepatocellular carcinoma therapies
  • Ewing sarcoma management

Studies are evaluating novel therapeutic approaches for improving patient outcomes in challenging pediatric cancers.

02 Rare Genetic Disorders

Research initiatives addressing rare genetic conditions are exploring new treatment options for conditions affecting children and young adults.

  • Duchenne Muscular Dystrophy
  • Angelman Syndrome
  • Prader-Willi Syndrome
  • Hunter Syndrome

These trials aim to evaluate innovative therapies targeting specific genetic mechanisms.

03 Respiratory and Immunological Studies

Clinical research focusing on respiratory conditions and immunological responses, particularly in pediatric populations.

  • RSV prevention in high-risk infants
  • Allergic rhinitis treatments
  • Bronchopulmonary dysplasia management

Studies emphasize both preventive measures and therapeutic interventions for respiratory conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.